Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®

NCT06627478 | Completed Phase 1 FDA Drug

• 1 other identifier: NKF-INS(G)-101
• Study Type: interventional
• Target: 114
• Locations: 1 country
• Sites: 1

Brief Summary

Single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®

Conditions

Healthy Participants

Outcome Measures

Primary Outcomes (1)

• To compare the Pharmacokinetic (PK) of NKF-INS Glargine(G) to United States (US)-approved and European Union (EU)-authorized Lantus to demonstrate PK similarity for metabolite 21A-Gly-human insulin (M1)

  Area Under the Curve (AUC)0-24h of M1

  60 and 0 minutes pre-dose and 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours post-dose

Secondary Outcomes (4)

• To evaluate additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine

  60 and 0 minutes pre-dose and 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours post-dose

• To evaluate additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for M1

  60 and 0 minutes pre-dose and 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours post-dose

• To compare the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.

  Time Frame: 60 and 0 minutes pre-dose and 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours post-dose

• To assess the safety of NKF-INS(G)

  Day 1 to 7 weeks

Study Arms (3)

United States (US)-Lantus®

ACTIVE COMPARATOR

Single subcutaneous dose administered over three treatment periods

Drug: US-Lantus®

European Union (EU)-Lantus®

ACTIVE COMPARATOR

Single subcutaneous dose administered over three treatment periods

Drug: EU-Lantus®

NKF-INS Glargine (G)

EXPERIMENTAL

Single subcutaneous dose administered over three treatment periods

Drug: NKF-INS(G)

Interventions

NKF-INS(G) DRUG

Single subcutaneous dose of 0.5 IU/kg administered over three periods

NKF-INS Glargine (G)

US-Lantus® DRUG

Single subcutaneous dose of 0.5 IU/kg administered over three periods

United States (US)-Lantus®

EU-Lantus® DRUG

Single subcutaneous dose of 0.5 IU/kg administered over three periods

European Union (EU)-Lantus®

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Signed and dated informed consent obtained before any trial-related activities. Trial-related activities are any procedures that would not have been done during normal management of the participant.
• Healthy male participants
• Age between 18 and 50 years, both inclusive
• Body Mass Index between 18.5 and 29.0 kg/m2, both inclusive
• Body weight ≥ 59 kg
• Fasting glucose concentration ≤ 5.5 mmol/L at screening
• Considered generally healthy upon completion of medical history, physical examination, vital signs, electrocardiogram (ECG), and analysis of laboratory safety variables, as judged by the Investigator
• Willing and able to comply with scheduled visits, treatment plan, clinical laboratory tests, and other study procedures including lifestyle considerations.
• Participants must agree to use condoms during sexual intercourse. Additionally, female partners of male participants should use highly effective contraception. All contraceptive measures apply from screening until 90 days after study treatment. Male participants must refrain from donating or banking sperm for 90 days after administration of study treatment.
• Have competence in speaking, writing, and comprehending the local language(s) where the study is conducted.

You may not qualify if:

• Positive for human insulin antibodies at Screening
• Are currently enrolled in or have discontinued within 3 months or 5 half-lives (whichever is longer) of any investigational drug or device or are concurrently enrolled in any other type of medical research study and judged not to be scientifically or medically compatible with this study.
• Have known allergies to insulin, its excipients, or related drugs or have history of relevant allergic reactions of any origin, or any specific investigational product safety concern.
• History of diabetes mellitus; episodes of hypoglycemia in the anamnesis; any history of insulin use for treatment purposes.
• Have clinically relevant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data.
• Increased risk of thrombosis, e.g., individuals with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator.
• Clinically significant abnormal ECG at screening.
• Glycemia level ≥140 mg/dL 2 hours after the glucose load.
• Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
• Positive urine drug test at screening and/or evidence of current use of known drugs of abuse or have a history of use within the past year.
• Show evidence of an acute infection with fever or infectious disease at the time of enrollment.
• Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies at screening.
• Have positive test results for hepatitis B surface antigen (HBsAg), immunoglobulin M (IgM) antibody to hepatitis B core antigen (anti-HBc), or hepatitis C virus (HCV) antibodies at screening.
• Intend to use over-the-counter medication within 7 days or prescription medication within 14 days prior to dosing (apart from vitamin/mineral supplements, occasional paracetamol, thyroid replacement).
• Have donated blood or had a blood loss of 500 mL 3 months prior to study enrollment.

Sponsors & Collaborators

• Xentria, Inc.: lead

Study Sites (1)

FARMOVS Clinical Research Organisation

Bloemfontein, 9301, South Africa

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 30, 2024
• First Posted: October 4, 2024
• Study Start: October 29, 2024
• Primary Completion: July 3, 2025
• Study Completion: July 3, 2025
• Last Updated: July 16, 2025

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

ZA (1)